# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)

> **NCT07717905** · PHASE1,PHASE2 · RECRUITING · sponsor: **Bambusa Therapeutics** · enrollment: 48 (estimated)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** BBT001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07717905
- **Lead sponsor:** Bambusa Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-29
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07717905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07717905, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07717905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*